Technical Analysis for RCUS - Arcus Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 15.81 | 5.54% | 0.83 |
Earnings due: Aug 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 5.54% | |
| Outside Day | Range Expansion | 5.54% | |
| 20 DMA Resistance | Bearish | 8.51% | |
| 20 DMA Resistance | Bearish | 8.29% | |
| Hammer Candlestick | Bullish | 9.26% | |
| 20 DMA Resistance | Bearish | 10.71% | |
| Down 3 Days in a Row | Weakness | 10.71% | |
| Fell Below 20 DMA | Bearish | 7.33% |
| Alert | Time |
|---|---|
| Rose Above Upper Bollinger Band | about 8 hours ago |
| Upper Bollinger Band Resistance | about 8 hours ago |
| Up 5% | about 8 hours ago |
| Up 1 ATR | about 8 hours ago |
| 60 Minute Opening Range Breakout | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/05/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.47 |
| 52 Week Low | 12.96 |
| Average Volume | 733,374 |
| 200-Day Moving Average | 16.30 |
| 50-Day Moving Average | 15.60 |
| 20-Day Moving Average | 14.79 |
| 10-Day Moving Average | 15.02 |
| Average True Range | 0.78 |
| RSI (14) | 57.08 |
| ADX | 13.79 |
| +DI | 24.96 |
| -DI | 22.18 |
| Chandelier Exit (Long, 3 ATRs) | 13.81 |
| Chandelier Exit (Short, 3 ATRs) | 15.91 |
| Upper Bollinger Bands | 15.97 |
| Lower Bollinger Band | 13.61 |
| Percent B (%b) | 0.93 |
| BandWidth | 15.96 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.25 |
| MACD Histogram | 0.108 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.06 | ||||
| Resistance 3 (R3) | 16.95 | 16.43 | 16.85 | ||
| Resistance 2 (R2) | 16.43 | 16.11 | 16.48 | 16.78 | |
| Resistance 1 (R1) | 16.12 | 15.92 | 16.28 | 16.23 | 16.71 |
| Pivot Point | 15.60 | 15.60 | 15.68 | 15.65 | 15.60 |
| Support 1 (S1) | 15.29 | 15.28 | 15.45 | 15.40 | 14.91 |
| Support 2 (S2) | 14.77 | 15.09 | 14.82 | 14.84 | |
| Support 3 (S3) | 14.46 | 14.77 | 14.77 | ||
| Support 4 (S4) | 14.57 |
